REGISTER NOW TO BECOME A MEMBER

You are viewing the 1st of the 2 courses UPMC Physician Resources permits you to view without registering. To have full access to our FREE courses on our website, please register or log in now.
Register

Evidence-based Approach to the Management of Dementia: How Biomarkers are Improving Our Understanding of Alzheimer's Disease

Publish Date: January 31, 2012 Last Modified: December 21, 2017 Expires: January 31, 2013
This course has been expired.

Dementia and an evidence-based approach to the medical management of Alzheimer's disease is the topic of this presentation by Dr. Oscar Lopez of UPMC's Department of Neurology.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Identify the risk factors for Alzheimer's disease
  • Recognize the pathological features of Alzheimer's disease
  • Recognize the role biomarkers play in the diagnosis of Alzheimer's disease

Reading Resources:

  1. Evolution of the diagnostic criteria for degenerative and cognitive disorders. Curr Opin Neurol. 2011 Dec;24(6):532-41. Lopez OL, McDade E, Riverol M, Becker JT. Department of Neurology Department of Psychiatry Department of Psychology, Alzheimer's Disease Research Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA Department of Neurology,
  2. Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. 2011;6(10):e25446. Epub 2011 Oct 13. Wolz R, Julkunen V, Koikkalainen J, Niskanen E, Zhang DP, Rueckert D, Soininen H, Lötjönen J; Alzheimer's Disease Neuroimaging Initiative. Biomedical Image Analysis Group, Department of Computing, Imperial College London, London, United Kingdom.
  3. Front Neurol. 2011;2:46. Epub 2011 Jul 14. Biomarkers in Alzheimer's disease. Riverol M, López OL. Department of Neurology, University of Pittsburgh School of Medicine Pittsburgh, PA, USA.

Disclosures:

Dr. Lopez receives grant support from the NIA and NIH-NIMH and is a consultant for Johnson & Johnson.

Accreditation Statement:

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Each physician should only claim credit commensurate with the extent of their participation in the activity. Other health care professionals are awarded (0.1) continuing education units (CEU) which are equivalent to 1.0 contact hours.

For your credit transcript, please access our website 4 weeks post-completion at http://ccehs.upmc.edu and follow the link to the Credit Transcript page. If you do not provide the last 5 digits of your SSN on the next page you will not be able to access a CME credit transcript. Providing your SSN is voluntary.

Release Date: 1/31/2012 | Last Modified On: 1/31/2012 | Expires: 1/31/2013

This presentation was part of UPMC’s Update in Internal Medicine 2011: Evidence-Based Approaches to Common Medical Problems.

This course has been expired.

Presenters

  • Oscar L Lopez MD
    Oscar L. Lopez, MD
    Dr. Oscar Lopez continues to be actively involved in research. He is the Director of the University of Pittsburgh Alzheimer?s Disease Research Center, the principal investigator of 3 NIH-funded grants, and he is co-investigator in other 6 NIH-funded projects, and consultant in another 3. Dr. Lopez is conducting a large-scale study in the clinical diagnosis of mild cognitive impairment (MCI), which is considered an intermediate state between normalcy and dementia. His findings are relevant to an understanding of the symptom profile and nosology of MCI. Dr. Lopez is currently conducting studies, as principal investigator and co-investigator, of the factors that modulate the transition from normal to mild cognitive impairment (MCI) and to dementia in relationship to cerebral amyloid deposition. These studies examine how cardiovascular and cerebrovascular factors create a vulnerability state for Alzheimer?s disease (AD) and neurodegeneration, and how they affect physiologically relevant compensatory mechanisms in the brain using MRI, FDG-PET, and Pittsburgh Compound B (PiB) technologies.
    full profile

Related Courses